Intraductal biliopancreatic imaging: European Society of Gastrointestinal Endoscopy (ESGE) technology review

This technology review expresses the current view of the European Society of Gastrointestinal Endoscopy (ESGE) on the available techniques for intraductal biliopancreatic imaging.

The three cholangioscopy techniques are described: the "dual-operator" and "single-operator" mother-baby approaches using dedicated instruments, and the "direct" technique using currently available ultrathin gastroscopes.

The mother-baby method is standardized and reproducible, while direct cholangioscopy is technically demanding and its safety requires further evaluation.

As well as direct visualization of the bile ducts, cholangioscopy has the further advantage of allowing targeted biopsy.

Image quality is still suboptimal for single-operator cholangioscopy, while the other techniques have achieved adequately detailed imaging.

The costs of mother-baby cholangioscopy are high and its application in clinical practice should be restricted to selected cases (i.e. indeterminate biliary strictures/intraluminal lesions, difficult biliary stones) and to the setting of tertiary care centers.

Peroral pancreatoscopy may find an indication in situations where other imaging modalities (mainly EUS) are inconclusive (i.e. delineation of main duct intraductal papillary mucinous neoplasia extension, sampling of indeterminate main pancreatic duct strictures)

Intraductal ultrasonography (IDUS) has a poorer performance than EUS in the staging of pancreatic malignancies and can increase the risk of pancreatitis. A promising indication for IDUS could be the evaluation of indeterminate biliary strictures and ampullary tumors.

Probe-based confocal laser endomicroscopy (pCLE) of the bile ducts is a difficult and expensive technique. Appropriate training needs to be established, since interpretation of images is challenging. pCLE can be an important diagnostic tool in the setting of indeterminate biliary strictures.

Bibliography

Published online: 6.7.2015
Endoscopy 2015; 47: 739–753
© Georg Thieme Verlag KG Stuttgart · New York
ISSN 0013-726X

Corresponding author
Andrea Tringali, MD PhD
Digestive Endoscopy Unit,
Catholic University
Largo A. Gemelli 8
00168 Rome, Italy
Fax: +39–06–30157220
andrea.tringali@rm.unicatt.it

Abbreviations

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Full Form</th>
</tr>
</thead>
<tbody>
<tr>
<td>3D-IDUS</td>
<td>Three-dimensional intraductal ultrasonography</td>
</tr>
<tr>
<td>CBD</td>
<td>Common bile duct</td>
</tr>
<tr>
<td>CI</td>
<td>Confidence interval</td>
</tr>
<tr>
<td>CLE</td>
<td>Confocal laser endomicroscopy</td>
</tr>
<tr>
<td>CT</td>
<td>Computed tomography</td>
</tr>
<tr>
<td>DOC</td>
<td>Double-operator cholangioscopy</td>
</tr>
<tr>
<td>EHL</td>
<td>Electrohydraulic lithotripsy</td>
</tr>
<tr>
<td>EPLBD</td>
<td>Endoscopic papillary large balloon dilation</td>
</tr>
<tr>
<td>ERC</td>
<td>Endoscopic retrograde cholangiography</td>
</tr>
<tr>
<td>ERCP</td>
<td>Endoscopic retrograde cholangio-pancreatoscopy</td>
</tr>
<tr>
<td>ESWL</td>
<td>Extracorporeal shockwave lithotripsy</td>
</tr>
<tr>
<td>EUS</td>
<td>Endoscopic ultrasonography</td>
</tr>
<tr>
<td>FNA</td>
<td>Fine needle aspiration</td>
</tr>
<tr>
<td>IPM</td>
<td>Intraductal papillary mucinous neoplasia</td>
</tr>
<tr>
<td>MRI</td>
<td>Magnetic resonance imaging</td>
</tr>
<tr>
<td>MRCP</td>
<td>Magnetic resonance cholangio-pancreatoscopy</td>
</tr>
<tr>
<td>NBI</td>
<td>Narrow band imaging</td>
</tr>
<tr>
<td>OR</td>
<td>Odds ratio</td>
</tr>
<tr>
<td>pCLE</td>
<td>Probe-based confocal laser endomicroscopy</td>
</tr>
<tr>
<td>POPS</td>
<td>Peroral pancreatoscopy</td>
</tr>
<tr>
<td>SOC</td>
<td>Single-operator cholangioscopy</td>
</tr>
</tbody>
</table>

Introduction

Endoscopic retrograde cholangiopancreatography (ERCP) is a diagnostic and therapeutic invasive imaging modality of the biliopancreatic duct
tal system. It provides an "indirect" radiological visualization of the biliopancreatic system. The first direct peroral visualization of the biliopancreatic system was described in 1975 [1] and it has since become an important diagnostic tool in selected cases, when other available techniques (e.g. endoscopic ultrasonography [EUS], computed tomography [CT] scanning, magnetic resonance imaging [MRI], biopsy sampling) cannot provide a definitive diagnosis. Therapeutic goals were then pursued, mostly the extraction of biliary and pancreatic stones using electrohydraulic or laser lithotripsy. The main drawbacks of cholangiopancreatoscopy include costs, suboptimal imaging quality, and the fragility of the devices. During the last 20 years, the development of high quality video cholangioscopes (Table 1) has partially resolved some of these problems. Intraductal biliopancreatic imaging modalities were expanded, with new and expensive techniques (Table 2) aiming at visualizing the thickness of duct walls as well as periductal structures (intraductal ultrasound, confocal laser endomicroscopy [CLE]).

This technology review expresses the current view of the European Society of Gastrointestinal Endoscopy (ESGE) about the presently available techniques for intraductal biliopancreatic imaging.

**Methods**

The aim of this technology review is to clarify technical aspects for those who actually perform endoscopic procedures [2]. The methodology was adapted from that used for ESGE clinical guidelines; notable differences include the absence of key questions and recommendations. In September 2013, the project was endorsed by the ESGE Governing Board. Different topics were each assigned to a subgroup of experts after a general discussion during a meeting held in October 2013 (Berlin, Germany). The final search of the relevant literature was performed in November 2014 using Medline (via Pubmed), the Cochrane Library, Embase, and the internet. In March 2015, a draft prepared by A. T. was sent to all group members. After agreement on a final version, the manuscript was reviewed by two members of the ESGE Governing Board and sent to all ESGE individual members for comments. It was then submitted to the journal *Endoscopy* for publication. This technological review was issued in 2015 and will be considered for update in 2019.

**Table 1** Characteristics of available “mother-baby” cholangiopancreatoscopes.

<table>
<thead>
<tr>
<th>Endoscope</th>
<th>Type</th>
<th>Operators, n</th>
<th>Tip diameter, mm</th>
<th>Working channel, mm</th>
<th>Image enhancement</th>
<th>Lumens, n</th>
<th>Tip deflection</th>
<th>Deflection angulation</th>
<th>Field view</th>
<th>Focal distance, mm</th>
<th>Working length, m</th>
</tr>
</thead>
<tbody>
<tr>
<td>CHF-BP30 (Olympus)</td>
<td>Fiber</td>
<td>2</td>
<td>3.1</td>
<td>1.2</td>
<td>No</td>
<td>1</td>
<td>2-way</td>
<td>290°: up 160° down 130°</td>
<td>90°</td>
<td>1–50</td>
<td>1.87</td>
</tr>
<tr>
<td>FCP-9P (Pentax)</td>
<td>Fiber</td>
<td>2</td>
<td>3</td>
<td>1.15</td>
<td>No</td>
<td>1</td>
<td>2-way</td>
<td>180°: up 90° down 90°</td>
<td>90°</td>
<td>1–50</td>
<td>1.9</td>
</tr>
<tr>
<td>CHF-B1601 (Olympus)</td>
<td>Video</td>
<td>2</td>
<td>4</td>
<td>1.2</td>
<td>No</td>
<td>1</td>
<td>2-way</td>
<td>140°: up 70° down 70°</td>
<td>90°</td>
<td>3–20</td>
<td>2</td>
</tr>
<tr>
<td>CHF-B2601 (Olympus)</td>
<td>Video</td>
<td>2</td>
<td>3.4</td>
<td>1.2</td>
<td>Yes (NBI)</td>
<td>1</td>
<td>2-way</td>
<td>140°: up 70° down 70°</td>
<td>90°</td>
<td>3–20</td>
<td>2</td>
</tr>
<tr>
<td>CHF-B2601 (Olympus)</td>
<td>Video</td>
<td>2</td>
<td>2.6</td>
<td>0.5</td>
<td>Yes (NBI)</td>
<td>1</td>
<td>2-way</td>
<td>140°: up 70° down 70°</td>
<td>90°</td>
<td>3–20</td>
<td>2</td>
</tr>
<tr>
<td>Spyglass (Boston Scientific)</td>
<td>Video</td>
<td>2</td>
<td>3.4</td>
<td>1.2</td>
<td>No</td>
<td>3</td>
<td>4-way</td>
<td>240°: up 60° down 60° right 60° left 60°</td>
<td>70°</td>
<td>1–50</td>
<td>2.3</td>
</tr>
<tr>
<td>Polyscope (Polydiagnost)</td>
<td>Video</td>
<td>2</td>
<td>2.7</td>
<td>1.2</td>
<td>No</td>
<td>1</td>
<td>1-way</td>
<td>180°: up 60° down 60°</td>
<td>70°</td>
<td>2–10</td>
<td>1.85</td>
</tr>
</tbody>
</table>

NBI, narrow band imaging.

1 Not commercially available in Europe.

**Dual-operator “mother-baby” peroral cholangioscopy**

**Introduction**

Dual-operator cholangioscopy (DOC) is commonly referred to as “mother-baby cholangioscopy”; it uses a very slim endoscope passed through the accessory channel of a duodenoscope. Two endoscopists are needed to control the instruments.

**Equipment and technique**

A biliary sphincterotomy is usually performed to facilitate passage of the cholangioscope (95% of 144 patients in a retrospective series) [3]. Then, the cholangioscope (“baby” scope) is passed through the accessory channel of the duodenoscope (“mother” scope).
scope), usually over a guidewire for easier biliary cannulation. Once the target area has been reached, the guidewire is removed to enhance visualization and to allow the use of the working channel. Irrigation with sterile saline is commonly used to provide a clear view of the bile duct, while carbon dioxide has been reported to be an interesting alternative in two small comparative nonrandomized series [4,5]. Briefly, the two studies found a shorter procedure time with carbon dioxide versus saline and, in one study [4], a better image quality. Bile is removed from the bile duct through the working channel of the choledochoscope using a syringe; no significant increase in venous Pco2 levels was recorded after the procedure [4]. Possible interventions during mother-baby cholangioscopy include forceps biopsy sampling and electrohydraulic/laser lithotripsy under direct vision [6].

### Diagnostic indications

In patients with bile duct strictures and unclear filling defects, adding cholangioscopic appearance data to biopsy sampling/brush cytology under fluoroscopic or cholangioscopic guidance may improve the diagnostic yield [Table 3] [3,7–9]. Characteristics of malignancy at DOC include thick, irregular, and tortuous vessels, irregular papillopluranal or nodular elevated surface, and a tendency to bleed easily. Characteristics of benign lesions include a fine network of thin vessels and a relatively flat surface, a homogeneous papillopluranal surface suggesting hyperplasia, a bumpy surface indicative for inflammation, or a whitish color with convergence of folds suggesting scars.

More recently, optical image manipulation using narrow band imaging (NBI) has been introduced for video cholangioscopy. In small prospective series (<30 cases) of patients with biliary strictures or filling defects, NBI greatly improved visualization and allowed the detection of lesions not visible with white light. For example, a better definition of the mucosal structure of intraductal papillary neoplasms of the bile duct was described with NBI cholangioscopy [10]. Improved visualization of the vascular pattern with NBI cholangioscopy was also found helpful for diagnosing indeterminate biliary strictures, and the information provided by the macroscopic appearance was judged more sensitive than brush cytology. The prospective multicenter study by Osanai et al., summarized in Table 3, used NBI.

Cholangioscopy, with or without NBI, was of little help in the evaluation of external biliary compression where the mucosa appears normal [11]. Further comparisons of NBI cholangioscopy with tissue sampling results are expected for a definition of its role. NBI cholangioscopes are not commercially available in Europe.

### Therapeutic indications

Guidance for lithotripsy (electrohydraulic lithotripsy [EHL] or laser lithotripsy) is the most common indication for DOC (Fig. 1). After failure of stone extraction during ERCP, cholangioscopy-guided EHL and laser lithotripsy were reported to allow duct clearance in 77%–96% of cases in four series that included 292 patients [12–15]. Stone recurrence was reported in 16%–18% of the patients after a mean follow-up of 2 to 5 years [13–15]. Median procedure duration (cholangioscopy+EHL/laser lithotripsy) was 2 hours in a Swedish series [14]; repeated treatment sessions have been required in nearly 20% of cases [12]. Interestingly DOC-guided lithotripsy was successfully used in 50 patients with type II Mirizzi syndrome, obtaining stone clearance in 48% (96%) [15]. EHL and laser lithotripsy can be used also under fluoroscopic control; DOC-guided lithotripsy has been recommended for intrahepatic stones and stones proximal to a bile duct stricture [16].

### Complications and limitations

A retrospective study that compared ERCP with versus without cholangiopancreateoscopy (n=402 vs. n=3475, respectively) showed increased morbidity if cholangiopancreateoscopy was performed (odds ratio [OR] 2.50, 95% confidence interval [95% CI] 1.56–3.89), in particular for cholangitis (OR 4.98, 95%CI 1.06–19.67) [17]. A proposed mechanism for the increased risk of cholangitis is the use of intermittent intraductal irrigation dur-

---

**Table 2** Estimated costs (in euros) of intraductal biliopancreatic imaging devices commercially available (in Europe).

<table>
<thead>
<tr>
<th>Technique</th>
<th>Imaging console</th>
<th>Endoscope/catheter/optical fiber/probe</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Dual-operator “mother-baby” fiber pancreatocholangioscope</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Olympus, CHF-BP30</td>
<td>Standard light source</td>
<td>16 000 €</td>
</tr>
<tr>
<td>Pentax, FCP-9P</td>
<td>Standard light source</td>
<td>18 500 €</td>
</tr>
<tr>
<td><strong>Dual-operator “mother-baby” video pancreatocholangioscope</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Polidygnost, Polyscope</td>
<td>45 000 €</td>
<td>Catheter (single use) 1000 €</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Optical fiber 10 000 €</td>
</tr>
<tr>
<td><strong>Single-operator “mother-baby” video pancreatocholangioscope</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Boston Scientific, SpyGlass</td>
<td>65 000 €</td>
<td>Catheter (single use) 1400 €</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Optical fiber (20 uses) 5000 €</td>
</tr>
<tr>
<td><strong>Direct cholangioscopy (transnasal gastroscopes)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Olympus, GIF-N180</td>
<td>Standard videoprocessor</td>
<td>29 000 €</td>
</tr>
<tr>
<td>Pentax, EG16-K10</td>
<td>Standard videoprocessor</td>
<td>27 000 €</td>
</tr>
<tr>
<td>Fuji, EG-530NP</td>
<td>Standard videoprocessor</td>
<td>28 500 €</td>
</tr>
<tr>
<td><strong>Intraductal ultrasonography</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(Olympus)</td>
<td>65 000 €</td>
<td>Probe (reusable) 7000 €</td>
</tr>
<tr>
<td><strong>Confocal laser endomicroscopy</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mauna Kea, Cellvizio</td>
<td>150 000 €</td>
<td>Probe (10 uses) 8000 €</td>
</tr>
</tbody>
</table>
ing cholangioscopy. Complications of cholangioscopy with EHL (cholangitis, hemobilia, biliary leak, bradycardia) have been reported in up to 18% of cases [12]. Therefore, patients should be carefully selected before being subjected to cholangiopancreatoscopy. Antibiotic prophylaxis is important; additionally biliary drainage should be considered in selected cases following cholangioscopy.

The main limitations of DOC remain the need for two operators, and the cost and fragility of the equipment [18]: in a series including 21 patients the cholangioscope malfunctioned on the 22nd procedure [19].

Conclusion
Dual-operator cholangioscopy is a standardized and reproducible technique that now has good image quality. Because of costs, complexity, and procedure-related morbidity, it should be considered in selected cases only, in particular for some indeterminate biliary strictures/intraluminal lesions, and difficult biliary stones, and only in the setting of tertiary care centers. Standardization of visual diagnostic criteria for benign and malignant lesions, with and without image-enhancement technology, is expected from future studies.

**Single-operator “mother-baby” peroral cholangioscopy**

**Introduction**
Single-operator cholangioscopy (SOC) was introduced by Boston Scientific (Natick, Massachusetts, USA) with the SpyGlass direct visualization system. Its most distinctive feature is the capability for a single endoscopist to perform cholangiopancreatoscopy using the “mother-baby” method, by securing the access and delivery catheter to the duodenoscope handle. It includes disposable and reusable parts as well as a dedicated image processor. Equipment and technique
The Spyglass system includes a 10-Fr access and delivery catheter with a 1.2-mm-diameter working channel, a 0.9-mm-diameter channel for the reusable optical probe, and two dedicated 0.6-mm-diameter irrigation channels. The access catheter is introduced through a duodenoscope with a minimum working channel diameter of 4.2mm. The tip of the catheter can be deflected by at least 30 degrees in the four directions, which is an improvement over the single-plane deflection tip of most reusable baby endoscopes. The dedicated irrigation channels contribute to obtaining a clear optical field during the procedure. A dedicated disposable 3-Fr biopsy forceps is available. SOC-guided tissue sampling and intraductal lithotripsy are possible through the working channel of the access catheter. Other components consist of a video monitor and a travel cart housing the light source, a camera, an insulated transformer, and an irrigation pump with a footswitch.

---

**Table 3** Results of intrabiliary tissue sampling combined or not with double-operator cholangioscopy (DOC) for the diagnosis of malignancy in selected series.

<table>
<thead>
<tr>
<th>First author, year Modality</th>
<th>Patients, n</th>
<th>Sensitivity, %</th>
<th>Specificity, %</th>
<th>Accuracy, %</th>
<th>Study design (data collection)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fukuda, 2005 [7] ERC/tissue sampling1</td>
<td>90</td>
<td>57</td>
<td>100</td>
<td>78</td>
<td>Prospective</td>
</tr>
<tr>
<td>ERC/tissue sampling1 + DOC</td>
<td>100</td>
<td>86</td>
<td>93</td>
<td></td>
<td></td>
</tr>
<tr>
<td>P value</td>
<td></td>
<td></td>
<td></td>
<td>P&lt;0.05</td>
<td>P&lt;0.05</td>
</tr>
<tr>
<td>Itoi, 2010 [3] ERC/tissue sampling2</td>
<td>120</td>
<td>86</td>
<td>79</td>
<td>85</td>
<td>Retrospective</td>
</tr>
<tr>
<td>ERC/tissue sampling2 + DOC</td>
<td>99</td>
<td>95</td>
<td>98</td>
<td></td>
<td></td>
</tr>
<tr>
<td>P value</td>
<td></td>
<td></td>
<td></td>
<td>P&lt;0.001</td>
<td>P&lt;0.001</td>
</tr>
<tr>
<td>Nishikawa, 2011 [8] DOC guided biopsy forceps</td>
<td>33</td>
<td>38</td>
<td>100</td>
<td>60.6</td>
<td>Prospective</td>
</tr>
<tr>
<td>DOC visual finding</td>
<td>100</td>
<td>91</td>
<td>97</td>
<td></td>
<td></td>
</tr>
<tr>
<td>P value</td>
<td></td>
<td></td>
<td></td>
<td>P&lt;0.0018</td>
<td></td>
</tr>
<tr>
<td>Osanai, 2013 [9] Tissue sampling3</td>
<td>35</td>
<td>81</td>
<td>100</td>
<td>85</td>
<td>Prospective</td>
</tr>
<tr>
<td>DOC + NBI visual finding</td>
<td>96</td>
<td>80</td>
<td>92</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

ERC, endoscopic retrograde cholangiography; NBI, narrow band imaging.
1 Endobiliary sampling under fluoroscopic guidance using biopsy forceps (n = 24) and brush cytology (n = 66).
2 Endobiliary biopsy forceps under fluoroscopic guidance and DOC-guided biopsy forceps.
Diagnostic applications
SOC with the SpyGlass system has a reported success rate of >90% [20–23]. The main indication for SOC is the evaluation of biliary strictures (Fig. 2) and filling defects. The mean sensitivity of biliary sampling, using the dedicated 3-Fr biopsy forceps, for discriminating between malignant and benign biliary lesions was 68% [20–26] (Table 4), slightly higher than those reported for brushing (59%) and biopsy (63%) in the setting of cholangiocarcinoma [27]. The sensitivity of SOC appearance was also assessed in two prospective trials and it was found to be higher (84%–95%) than that of biopsy sampling (49%–82%) [20,26]. However, the value of subjective “impressions,” as against hard data such as provided by a biopsy sample, is questionable at a stage of disease work-up that is advanced enough for performance of direct biliopancreatic imaging. Furthermore, interobserver agreement for diagnosis using SOC appearance is only fair [28]. In a prospective multicenter study, the sensitivity of SOC-directed biopsy sampling was far higher for intrinsic (66%) than for extrinsic (8%) malignant lesions [20].

Less common settings in which SOC has been used include the evaluation of cystic lesions in the biliary tract, precise mapping and delineation of cholangiocarcinoma before resection, confirmation of bile duct stone clearance, and evaluation of the biliary tract after bile duct surgery and after liver transplantation [29,30]. The incremental information obtained through SOC compared with ERCP alone in these situations remains to be determined.

Therapeutic applications
The major therapeutic indication for SOC is lithotripsy for difficult biliary stones. SOC-guided lithotripsy has been reported as effective and safe with a success rate of 90%–100% and a decreased need for mechanical lithotripsy [20,21,31]. This technique would currently compete with endoscopic papillary large balloon dilation (EPLBD) for bile duct stone extraction. A recent meta-analysis of EPLBD has found an overall stone clearance rate of >95% with decreased use of mechanical lithotripsy [32]. Advantages of SOC over EPLBD include the possibility to treat larger biliary stones and to extract pancreatic stones (although this should be limited to highly specialized centers) [33]. A potential advantage of SOC is its ability to better assess bile duct clearance than ERCP; the latter has been reported to fail to identify residual bile duct stones in 8%–16% of cases, although the clinical significance of residual stones identified at SOC remains to be elucidated [21]. Disadvantages of SOC compared with EPLBD include the cost of the disposable devices and of the specific equipment (SOC plus lithotripsy device); thus, its most profitable use could be limited to extraction of stones that cannot be removed using EPLBD.

Other reported therapeutic uses of SOC include treatment of anatomistic biliary strictures and of biliary casts after liver transplant [34], transpapillary gallbladder drainage in acute cholecystitis [35], removal of foreign body [36], retrieval of migrated pancreatic stents [37], and assistance in guidewire placement.

Complications and limitations
As stated in the section on mother-baby cholangioscopy, patients should be carefully selected before being subjected to cholangioscopy-directed therapy cholangioscopy-directed biliary biopsy sampling for the diagnosis of malignancy in selected series.

Table 4 Sensitivity of single-operator cholangioscopy-directed biliary biopsy sampling for the diagnosis of malignancy in selected series.

<table>
<thead>
<tr>
<th>First author, year</th>
<th>Patients, n</th>
<th>Sensitivity, % (n/n)</th>
<th>Study design (data collection)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chen, 2007 [20]</td>
<td>20</td>
<td>71 (5/7)</td>
<td>Prospective</td>
</tr>
<tr>
<td>Chen, 2011 [21]</td>
<td>95</td>
<td>49 (22/45)</td>
<td>Prospective</td>
</tr>
<tr>
<td>Ramchandani, 2011 [26]</td>
<td>22</td>
<td>82 (18/22)</td>
<td>Prospective</td>
</tr>
<tr>
<td>Draganov, 2012 [22]</td>
<td>26</td>
<td>76 (13/17)</td>
<td>Prospective</td>
</tr>
<tr>
<td>Hartmann, 2012 [23]</td>
<td>106</td>
<td>57 (16/28)</td>
<td>Retrospective</td>
</tr>
<tr>
<td>Manta, 2013 [25]</td>
<td>42</td>
<td>88 (37/42)</td>
<td>Prospective</td>
</tr>
<tr>
<td>Total</td>
<td>435</td>
<td>68 (146/214)</td>
<td></td>
</tr>
</tbody>
</table>

Direct cholangioscopy
Introduction
Direct cholangioscopy refers to the use of nonspecific endoscopes, usually ultraslim endoscopes designed for pediatric or transnasal esophagogastroduodenoscopy, to directly enter the common bile duct (CBD); it was first described in 1977.
Equipment and technique

Direct cholangioscopy requires previous ERCP with a large endoscopic sphincterotomy and/or sphincteroplasty. Different direct cholangioscopy techniques have been reported:

- **The tandem technique** consists of introducing a guidewire into the CBD, withdrawing the duodenoscope and then backloading the wire into an ultraslim endoscope that is advanced over the wire into the CBD under fluoroscopic guidance. Wire dislocation is frequent with this technique [38].

- **Freehand intubation** has been used in the majority of recent studies. The endoscope is manipulated to assume a “J” configuration in front of the sphincterotomy, and a guidewire or a 5-Fr balloon catheter is inserted in an intrahepatic bile duct or upstream from a stricture. The endoscope is then advanced over the guide into the bile ducts [39]. For interventional procedures, the balloon catheter must be withdrawn from the working channel of the endoscope, which may make the endoscope position unstable. Additionally, firm anchoring of the intraductal balloon can in some cases be difficult, especially in patients without intraductal stenoses or with extreme CBD dilation. A dedicated anchoring balloon was withdrawn by the manufacturer shortly after it became available, because of reports of fatal air embolism during the procedure [40].

- **Overtube balloon-assisted direct cholangioscopy** has also been reported [41]. However, the currently available overtubes are very large relative to ultraslim endoscopes, making it difficult to manipulate both the overtube and the endoscope. Therefore, further development of a more appropriate accessory is required to improve the interventional performance of direct cholangioscopy.

Technical success rates

An anchoring balloon (15 mm diameter, 5-Fr channel; MTW Endoskopie, Wesel, Germany) is recommended if the freehand intubation technique is used: in a comparative nonrandomized study, success rates with an anchoring balloon vs guidewire alone were 95.2% vs. 45.5%, respectively [38]. Similar success rates (88% and 81%) were reported with the balloon anchoring technique in smaller series of patients [42, 43, 44]. The overtube balloon-assisted direct cholangioscopy technique was reported to be successful in 10 of 12 patients (83%) [41]. Success rates were similar for direct cholangioscopy and mother-baby techniques in a randomized controlled trial [45].

Diagnostic applications

High resolution imaging (Fig. 3) and virtual chromoendoscopy may help to discriminate neoplastic from non-neoplastic structures on the basis of irregular vascular patterns and surface features [45]. So far however, visual criteria for malignancy, and corresponding diagnostic yields, have not been fully established. The large diameter of the working channel permits passage of a large biopsy forceps, which may increase the diagnostic yield.

Therapeutic applications

The 2.0-mm working channel of ultraslim upper gastrointestinal endoscopes used for direct cholangioscopy permits a wide array of therapeutic interventions, the most common being CBD stone removal. Small biliary stones can be removed under direct visual control using 5-Fr baskets or other accessories [46]; large stones can be treated using laser or EHL lithotripsy [38, 42, 47]. Intraductal neoplasia has been treated using argon plasma coagulation [42, 48, 49]. Direct placement of a 5-Fr stent or of a transnasal drain after selective guidewire insertion has also been reported [50]. If a complex biliary stricture cannot be traversed at ERCP, direct cholangioscopy may enable identification of the stricture site, biopsy sampling, and direct drainage [51].

Complications and limitations

The safety of direct cholangioscopy is questionable because of the occurrence of rare but severe adverse events, in particular stroke caused by leakage of air into the portal or hepatic venous system, which may pass through a patent foramen ovale to the left circulation [43, 52–54]. This complication is probably related to the increased intrabiliary pressure due to intraductal air insufflation combined with papillary obstruction by the endoscope. To lower the risk of such serious complications we strongly recommend the following safety measures, although it must be acknowledged that their efficacy has not been tested:

1. Keep gas insufflation to an absolute minimum, or even better, use carbon dioxide or saline irrigation rather than air to clear the bile duct.

2. Establish a wide papillary opening before the endoscope is inserted into the CBD. To this end, we carry out a large sphincterotomy or supplement the sphincterotomy with balloon dilation up to 10 mm.

3. If feasible, avoid mucosal trauma on the day of direct cholangioscopy, as the reported cases of air embolization occurred mainly during sphincterotomy.
Anchoring balloons may also involve a specific risk as, in an animal study, overinflation of the anchoring balloon resulted in biliary perforation [55]. The device was later voluntarily withdrawn from the market by the manufacturer, but these reported adverse events should prompt investigators to be very cautious in ensuring that anchoring balloons are not overinflated.

In the largest series published so far [42], the incidence of postprocedural cholangitis was 10% although patients were treated with periprocedural prophylactic antibiotics. In most cases direct cholangioscopy is limited to the examination of the CBD only, as the endoscope cannot be entered into small diameter bile ducts [45]. On the other hand, direct cholangioscopy is less costly than mother-baby technologies as no purchase of a dedicated cholangioscopy system is required, the system is more robust, and the endoscope may be used for esophagogastroduodenoscopy. Advantages and limitations of direct cholangioscopy compared with mother-baby technologies are listed in Table 5.

**Conclusion**

Direct cholangioscopy is a technically demanding technique limited to the examination of the CBD, and its safety needs further investigation. Prospective comparisons of direct cholangioscopy versus mother-baby technologies are expected to identify the optimal application of each technique.

**Pancreatoscopy**

**Introduction**

Since the introduction of fiberoptic cholangiopancreatoccopy, technological refinements have permitted the development of new ultrathin devices that do not require pancreatic sphincterotomy for their introduction, as well as of larger devices with a working channel that allows the passage of biopsy forceps and that have four-way tip deflection that improves maneuverability within the duct. Electronic pancreatoscopes with improved optical resolution (Fig. 4) or NBI modality allow the detection and characterization of the vascular pattern of tumors and of mucosal appearances.

**Fig. 4** Peroral video pancreatoscopy. a Normal main pancreatic duct. b Narrow band imaging mode enhancing abnormal vessels in the cystic portion of a main duct intrapapillary mucinous neoplasm (IPMN) at the tail of the pancreas.

**Equipment and technique**

The technical characteristics of different fiberoptic endoscopes used for peroral pancreatoscopy (POPS) and cholangioscopy are listed in Table 1. The 2.6–4-mm-diameter pancreatoscopes can be passed through the 4.2-mm working channel of a therapeutic duodenoscope. The 1.2-mm working channel of the pancreatoscope permits use of a 0.035-inch guidewire, a 3-Fr biopsy
forceps, EHL, or laser lithotripsy. Video adapters convert the fiberoptic image to a video format. Video pancreatoscopes with a large external diameter (5.2 mm) cannot be passed through duodenoscopes but thinner models (2.6 mm) are under investigation [56, 57].

The introduction of the endoscope through the papilla is similar to that described for mother-baby cholangioscopy, most commonly through the major papilla although it may also be possible through the minor papilla [58]. In the absence of a patulous orifice typical of intraductal papillary mucinous neoplasia (IPMN), a pancreatic sphincterotomy might be necessary, depending on the device diameter [59]. After introduction of the pancreatoscope into the main pancreatic duct, a guidewire might be necessary to reach the caudal portion of the main pancreatic duct. The main pancreatic duct is often examined under irrigation with saline to clear the view and under fluoroscopy to locate lesions [59]. In some reports, secretin (100 IU, intravenous) was used to stimulate the exocrine function and thus clear the view [60].

The Spyglass system, initially used for cholangioscopy, can provide better maneuverability within the main pancreatic duct than other endoscopes used for POPS. Recently, direct POPS has been described, that uses ultraslim 4.9-mm gastroscopes, employing two techniques:

- A 5-Fr anchoring balloon catheter is inflated in the main pancreatic duct in patients with suspected IPMN [61].
- An overtube is used to prevent stomach loop formation during insertion of the ultraslim gastroscope over a guidewire left in the main pancreatic duct [62]. In a variation of the technique, the overtube was punctured at 65 cm from its end to allow passage of the ultraslim gastroscope [63].

**Diagnostic applications**

**Intraductal papillary mucinous neoplasia (IPMN)**

IPMNs are mucin-producing tumors that involve the pancreatic duct mucosa and may present various degrees of malignant potential. They can be classified into three types: main duct, branch duct, and mixed-type IPMNs. The distinction between these different types is usually made at MRI; it helps to define adequate patient management [64].

POPS has been used to detect features associated with high risk of malignancy (protruding lesions, some vascular patterns); to define the extent of main pancreatic duct lesions prior to surgery, in order to select the parts of the pancreas to be resected; or to collect samples. The literature shows that:

- POPS has been reported in patients with IPMN in 6 series with a total of 185 patients [65 – 70]; the success rate was > 90% for the SpyGlass system [65, 69].
- Pancreatic sphincterotomy was not required in most recent series using mother-baby pancreatoscopy [66, 67, 70], while it was required in 38% – 93% of SpyGlass cases [65, 69].
- Mild to moderate pancreatitis following POPS was reported in 0 – 17% of cases [65, 67, 68, 70]; one death due to pancreatitis and respiratory failure has been reported [65].
- Various endoscopic features associated with malignancy at pancreatoscopy have been described. In the largest series published to date, protruding lesions were classified into five groups according to their appearance at POPS, and this allowed discrimination of malignant from benign IPMNs with an accuracy of 88% for main duct IPMNs and 67% for branch duct IPMNs [66]. Recently developed video pancreatoscopes with NBI allow better identification of malignant IPMN features, such as small protrusions and vessels [67]. The role of NBI-assisted pancreatoscopy needs to be evaluated in large series (Video 1).

- Pancreatoscopy can be useful to assess main duct IPMN extent preoperatively: a few cases of POPS-aided identification of the excision margins have been reported [67, 69], and a technique for a “POPS guided tattoo” may be developed in the near future. Intraoperative pancreatoscopy has been reported in a few cases; it seemed effective in identifying the resection margins [71] and in discovering skip lesions along the main pancreatic duct [72].

A prospective study of 44 patients with IPMN found that POPS affected clinical decision-making in 76% of cases, improving diagnosis accuracy compared to multidetector CT scan [65]. In the case of surgery for IPMN, the utility of preoperative POPS/IDUS versus peroperative frozen sections has not been compared.

**Indeterminate strictures of the main pancreatic duct**

Distinct duct patterns have been associated with main pancreatic duct strictures of various etiologies: coarse mucosa with friability and tumor vessels in the case of cancer; smooth stenosis without significant mucosal changes in the case of benign stricture. However, in a study that included 115 pancreatoscopy attempts, the area of interest in the main pancreatic duct could be visualized in only 56% of pancreatic cancers that were > 2 cm [59]. This poor visualization rate resulted from difficulties in obtaining a frontal view of lesions > 2 cm, that typically cause a long, asymmetrical, main pancreatic duct stenosis. In the same study, visualization rates for pancreatic cancers > 2 cm, benign strictures, and IPMN were 75%, 80%, and 95%, respectively. Although the accuracy of POPS has not been reported in this indication, POPS might help to characterize indeterminate main pancreatic duct strictures in a few highly selected cases with inconclusive findings from EUS-guided fine needle aspiration (FNA), as suggested by different non-controlled series [59, 60, 73].
**Sampling**

Tissue sampling during POPS is technically difficult because of the limited maneuverability of the biopsy forceps in the pancreatic ducts. Recently, a few series with new pancreatoscopes and ultrathin forceps have reported the performance of pancreatic ductal biopsies under direct visualization by POPS, but data are too limited to assess the accuracy of sampling for histopathological examination [58, 65].

Cytopathological examination of pancreatic juice collected during POPS, although rarely performed in Western countries, may be more useful, in particular in patients with IPMN. In a study that included 102 patients with surgically resected IPMN [74], pancreatic juice adequate for cytological diagnosis could be collected in 99% of patients. Sensitivity for the diagnosis of malignant IPMN was significantly higher if the pancreatic juice had been collected through POPS while observing the lesion, or from a position close to the lesion, compared with collection using a catheter (68% vs. 38%, respectively). Sensitivity was much lower for the diagnosis of non-IPMN pancreatic cancer (25%). Collection of pancreatic juice for cytopathological examination should be considered if POPS is performed in a patient with IPMN, in particular if EUS-FNA sampling has been non-contributive, for example because of the high viscosity of the mucus.

**Therapeutic applications**

**Intraductal lithotripsy in patients with chronic pancreatitis**

In a study that included 46 patients [75], intraductal lithotripsy was performed if a catheter could be passed upstream from obstructive main pancreatic duct stones at POPS; extracorporeal shockwave lithotripsy (ESWL) was recommended in the remaining cases. The number of stones treated by intraductal lithotripsy ranged from 2 to 4, and their median size was 8 mm; in 12 patients (26%), the stones were located in the head only. A mean of 2 POPS sessions were required to remove stones. Complete stone clearance from the main pancreatic duct was reported in 70% of patients. As ESWL is a well-established modality for removing main pancreatic duct stones that provides similar results, the role of intraductal lithotripsy will only be better defined when further studies become available.

**Complications and limitations**

After diagnostic and therapeutic POPS in large series, complications were reported in 10%–12% of patients and mostly consisted of mild pancreatitis [59, 75]. Anatomical factors may limit the success of POPS, namely tortuous, narrow, or structured ducts as well as obstructing stones or, in the case of IPMN, tumor location in the branch ducts [76]. The global visualization rate of the area of interest in large series reached 70%–80%, depending on the indication, as outlined in the section on indeterminate main pancreatic duct strictures. A minimum main pancreatic duct diameter of 5 mm is advocated by some authors as a requirement before POPS is attempted.

**Conclusion**

POPS has mostly been used in selected patients with main duct IPMN, chronic pancreatitis, or indeterminate main pancreatic duct strictures following EUS-FNA. A promising indication for POPS can be the preoperative delineation of main duct IPMN.

**Intraductal ultrasonography**

**Introduction**

Intraductal ultrasonography (IDUS) was first described in 1992. It consists of real-time ultrasonographic imaging of the biliary or pancreatic duct using a thin caliber ultrasonic probe (Table 6). High frequencies are used with IDUS, conferring high resolution at the cost of limited penetration depth (29 mm and 18 mm with the 12-MHz and 20-MHz probes, respectively).

**Table 6** Ultrasound miniprobe features.

<table>
<thead>
<tr>
<th>Manufacturer</th>
<th>Probe working length, m</th>
<th>Probe diameter, mm</th>
<th>Probe frequencies, MHz</th>
</tr>
</thead>
<tbody>
<tr>
<td>Olympus</td>
<td>2.14–2.20</td>
<td>2–2.9</td>
<td>12, 15, 20, 30</td>
</tr>
<tr>
<td>Fujinon</td>
<td>1.70–2.20</td>
<td>2.6</td>
<td>7.5, 12, 15, 20</td>
</tr>
</tbody>
</table>

**Equipment and technique**

IDUS is performed using a thin caliber ultrasonic probe consisting of a sheath catheter, transducer, and cable. The use of wire-guided IDUS probes is strongly advised because they can be inserted without biliary sphincterotomy in virtually all cases (and without dilation in many biliary strictures). The mechanical rotation of the transducer provides a cross-sectional image of the structures around the probe (Fig. 5). An ultrasound scan is performed at least twice from the hepatic hilum to the papilla of Vater alongside the guidewire or from the tail of the pancreas to the head. Fluoroscopic control is required for precise control of probe location.

Three-dimensional IDUS (3D-IDUS) has emerged as an interesting alternative to two-dimensional IDUS [77]. Probes that allow 3D-IDUS have an immobile outer sheath and an mobile inner radial transducer; they must be connected to a specific driving unit.

**Fig. 5** Intraductal ultrasound. The 20-MHz miniprobe shows a diffuse thickening of the common bile duct (arrow) secondary to cholangiocarcinoma (infiltrating type). W, duct of Wirsung.
After insertion of the probe up to the hilum, the driving unit is activated, and this withdraws the ultrasonic transducer inside the immobile outer sheath at a constant speed. Reconstructions may be provided in real time. Electronic storage of data allows, together with standardization of the procedure, the interpretation of 3D-IDUS images after completion of the ERCP, for example by an experienced echoendoscopist even if he/she did not attend the procedure.

**Indications**

**Choledocholithiasis**

IDUS presents a high diagnostic yield for bile duct stones. In a prospective comparative study, the sensitivities of magnetic resonance cholangiopancreatography (MRCP), ERCP, and IDUS for identifying choledocholithiasis were 80.0%, 90.0%, and 95.0%, respectively [78]. IDUS can differentiate stones (echogenic foci with acoustic shadowing) from air bubbles (echoic foci with reverberation artefacts) and biliary sludge (echogenic foci without acoustic shadowing).

Studies have attempted to delineate indications where IDUS could be most useful. Stones that are small (<8 mm) and located in a large CBD (>12 mm) are the most likely to be missed at ERCP and detected at IDUS, as shown in a retrospective study [79]. Therefore, the authors suggested that patients at high risk of having CBD stones but with negative ERCP findings should be selected for IDUS (rather than performance of biliary sphincterotomy or withdrawal of an inflated balloon in the CBD if no stone is evidenced).

Evaluation of patients with idiopathic recurrent pancreatitis is another possible indication for IDUS. In a prospective study, this technique allowed identification of a cause of idiopathic recurrent pancreatitis in 42% of 31 patients; the cause was mostly CBD stones not detected at ERCP [80]. A limitation of that study was the absence of EUS prior to IDUS.

Another potential indication for IDUS in biliary stone disease is the verification of stone clearance after supposedly complete stone extraction at ERCP [81–83]. In a nonrandomized comparative study that involved 188 patients [84], 59 patients had IDUS at the end of ERCP with supposedly complete CBD stone extraction; 24% of them had small residual stones not seen on cholangiography and these stones were extracted. At 3-year follow-up, CBD stone recurrence was detected in 3.4% of these patients compared with 13.2% of historical controls who had no IDUS (P<0.05).

**Bile duct strictures**

IDUS is highly accurate in distinguishing between benign and malignant biliary strictures [85] (Table 7). Even though it does not provide a pathological diagnosis, IDUS is more accurate than ERCP with transpapillary biopsies in distinguishing between benign and malignant strictures: in a retrospective study that compared IDUS versus combined ERCP/biliary sampling in 30 patients, IDUS presented a higher diagnostic accuracy than ERCP (90% vs. 67%), a higher specificity (92% vs. 42%) and a similar sensitivity (89% vs. 83%) [86]. Compared with EUS in a prospective study of 56 patients with indeterminate bile duct strictures, IDUS was more accurate (89% vs. 75%), more sensitive (91% vs. 75%), and more specific (80% vs. 75%). This difference was related to the proximal location and/or to the small size of some tumors that make EUS assessment difficult [87]. The superiority of IDUS compared with EUS was confirmed by another group of authors in a series of 30 patients [88]. Finally, a large retrospective study that included 234 patients with an indeterminate biliary stricture (136 of them with a final diagnosis of malignancy) confirmed these data: accuracies for the diagnosis of malignancy were IDUS 91%, transpapillary biopsy 59%, and EUS 74% [89].

IDUS features identified as independently associated with a malignant diagnosis, in a prospective study of 62 patients with an indeterminate biliary stricture, were: (i) presence of a sessile tumor (intraductal or outside of the bile duct); (ii) tumor size greater than 10.0 mm; and (iii) interrupted wall structure [90]. If none of these three features were present, the negative predictive value of IDUS for malignancy was close to 90%. On the other hand, when IDUS showed two or three of these features, a final diagnosis of malignancy was made in 97% of cases. Therefore, patients with two or three IDUS features predictive of malignancy should be managed as having a malignancy even if preoperative pathological findings are benign.

Finally, as IDUS is limited by the lack of pathological diagnosis, some investigators have performed IDUS-directed biopsy sampling (with the IDUS probe and a biopsy forceps introduced together in the working channel of the duodenoscope). Using this approach, a higher sensitivity for cancer diagnosis was obtained with IDUS-guided biopsy (87%) in comparison with fluoroscopically guided biopsy (67%) of indeterminate biliary strictures [91].

New techniques are being developed to facilitate IDUS-guided bile duct biopsy.

For T staging of cholangiocarcinoma, the accuracy of IDUS is superior to that of EUS, with the greatest difference noted for tumors located at the hilum [87]. Tamada et al. reported, in pioneer studies using various types of probes (7.5, 15, 20, and 30MHz), a very high accuracy for T staging and for the diagnosis of vascular invasion (T staging, 82%; portal vein invasion, 100%; right hepatic artery invasion, 100%) [92]. These results were confirmed by other authors who reported accuracies close to 90% for the assessment of pancreas and portal vein invasion (the portal vein and the right hepatic artery are the most frequently invaded vessels, while the left and common hepatic arteries are less frequently invaded) [93]. Compared with angiography, IDUS yielded slightly better results for the assessment of hepatic artery and portal vein invasion (nonsignificant differences) [92]. Resectability is better predicted by IDUS than by EUS [87].

For N staging, IDUS presents a lower accuracy than EUS, even if this is not complemented with FNA (43% vs. 63%, respectively; P<0.05). Because of the limited penetration depth of IDUS, this technique is currently considered to be unreliable for complete lymph node assessment [87,94]. EUS coupled with FNA of lymph nodes is more useful for this purpose [95].

The longitudinal extent of cholangiocarcinomas is a critical factor for the planning of surgical resection. IDUS coupled with biopsy sampling is likely the best technique currently available to assess this parameter. In a prospective study of 19 patients with a cholangiocarcinoma, investigated by IDUS immediately after biliary cannulation, longitudinal spread was correctly assessed by IDUS in 84% of the cases versus 47% with ERC (P<0.05) [96]. Other studies have reported slightly less favorable results, in particular

<table>
<thead>
<tr>
<th>Tumor</th>
<th>Sensitivity, %</th>
<th>Specificity, %</th>
<th>Accuracy, %</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cholangiocarcinoma</td>
<td>98</td>
<td>98</td>
<td>92</td>
</tr>
<tr>
<td>Pancreatic cancer</td>
<td>94</td>
<td>90</td>
<td>91</td>
</tr>
<tr>
<td>Ampullary cancer</td>
<td>81</td>
<td>90</td>
<td>89</td>
</tr>
</tbody>
</table>

Table 7 Intraductal ultrasonography (IDUS) performance in the diagnosis of bile duct stenosis of uncertain etiology in a series of 397 patients [85].
with 3D-IDUS [97]. To overcome the shortcomings of IDUS, some authors have recently proposed the combination of IDUS with transpapillary biopsy sampling. In a prospective study of 44 patients with a cholangiocarcinoma investigated preoperatively, the longitudinal tumor extent was correctly assessed by IDUS on the hepatic and duodenal sides in, respectively, 77% and 61% of cases. In the same patients, the corresponding figures with IDUS plus biopsy sampling were 93% and 82%, respectively [both P values <0.05] [98].

Pancreatic malignancy
Although pancreatic adenocarcinomas located in the vicinity of biliopancreatic ducts may be visualized by IDUS, this technique is inferior to EUS for the diagnosis and staging of pancreatic cancer because of its low penetration depth. With respect to IPMN, IDUS has been used to differentiate benign from malignant IPMNs and to guide the extent of surgical resection:

- Some old series reported that IDUS had the highest accuracy among several imaging techniques (including CT, EUS, and POPS) for distinguishing benign from malignant IPMNs [66, 99]. Nevertheless EUS, not IDUS, is currently recommended in the consensus guidelines for the management of IPMN [64]. Disadvantages of IDUS compared with EUS include the necessity to deeply cannulate the main pancreatic duct, the absence of sampling, and its low penetration depth that impedes discrimination between in situ and invasive carcinoma.

- A randomized controlled trial allocated 40 patients to standard pancreatic imaging either complemented or not with IDUS to guide the extent of surgical resection [100]. For patients allocated to complementary IDUS, the diagnostic accuracy for tumor extent of IPMN was 85% compared with 50% for controls (P<0.05). In a retrospective study of 24 patients with branch duct IPMN who were subjected to surgical resection, the extent of lateral spreading along the main pancreatic duct (defined as the detection of papillary protrusions within the main pancreatic duct beyond the area of the branch duct IPMN) was accurately assessed by IDUS in 92% of patients [101]. Lateral spreading was observed in patients with a main pancreatic duct of diameter >6 mm, who probably represent the population most likely to benefit from preoperative IDUS. The usefulness of IDUS should be compared with that of intraoperative examination of frozen sections of the surgical margins, using a standardized definition of positive resection margins, before definitive recommendations may be made [102].

Cancer/adenoma of the papilla of Vater
In a study that included 72 patients with a suspected ampullary tumor, IDUS had sensitivity, specificity, and accuracy for the diagnosis of ampullary carcinoma of 87.5%, 92.5% and 90.2%, respectively [103]. IDUS accuracy for T staging was in the range 71%–86%. For N staging, accuracy was 75%. Biopsy sampling had a lower sensitivity for the diagnosis of ampullary carcinoma (68%), so the authors suggested that IDUS should be combined with biopsy sampling to predict the cases in which endoscopic treatment is potentially feasible. However the possible applications of IDUS in both adenomas and papillary cancers have not been established.

Complications and limitations
IDUS has been reported to be an independent risk factor for post-ERCP pancreatitis (hazard ratio 2.41, 95% CI 1.33 – 1.49) in a series that included 2364 ERCP procedures [104]; in this series minip-}

robes were used without wire guidance, which might have contributed to the high rate of pancreatitis. In an older series of 239 patients who underwent IDUS of the pancreas, only one case of acute pancreatitis was reported, an incidence of 0.4% [105]. The main limitations of IDUS include costs, limited durability of the probe, limited penetration depth, and difficulty in evaluating intrahepatic ducts.

Conclusion
Indications for IDUS have not yet been established. This technique competes with EUS but it provides lower accuracy for the staging of pancreatic malignancies and no sampling capability. The most promising role for IDUS could be found in the evaluation of indeterminate biliary strictures and of ampullary tumors.

Confocal laser endomicroscopy

Introduction
Probe-based confocal laser endomicroscopy (pCLE) provides in vivo real-time, magnification of the mucosal layer, from a single cross-sectional plane perpendicular to the probe. A microscope transmits laser light is transmitted through a miniprobe and a distal lens sequentially scans the biliary epithelium in order to construct an image (Fig.6); images are displayed at 9–12 frames per second. The technique is currently available from a single company (Mauna Kea Technologies, Paris, France) [106].

Equipment and technique
The laser scanning unit may be connected to various probes. In the biliopancreatic ducts, two probes, namely the CholangioFlex and the GastroFlex probes, have been used. Microscopic images are obtained by placing the tip of the probe in contact with the duct wall, under fluoroscopic guidance or direct vision. Intravenous injection of 10% fluorescein sodium (1.0–5.0 ml) provides contrast that permits examination within approximately 10s and for 30–45 min. Topical application of cresyl violet has been abandoned in this indication. To obtain high quality images, the probe is maintained in a stable position, as perpendicular as possible to the duct wall, avoiding trauma because bleeding may decrease image quality. The characteristics of the two probes are as follows:

- The CholangioFlex measures 0.96 mm in diameter; it may be inserted into the biliary or pancreatic ducts through a catheter or through the working channel of a cholangioscope. The probe presents a radiopaque tip; it provides a magnification of ×400 with a depth of imaging from the surface of the confocal lens of 40–70 μm. The lateral resolution is 3.5 μm and the total field of view of an image is 325 × 325 μm.

- The GastroFlex presents a higher lateral resolution (1 μm) but it is larger (diameter 2.6 mm) and must be inserted into the CBD using the freehand technique, usually alongside a guidewire. Use of the Gastroflex in the bile duct has been reported by only a few authors, because it does not respond to movements of the duodenoscope ector [107].

Interpretation criteria
The Miami Classification consists of 18 criteria used as a standardized terminology for describing pCLE findings in the biliary as well as the pancreatic ducts; it has been developed on the basis of consensus by six investigators [108,109]. Five of these criteria, namely the detection of white bands >20 μm, of dark
bands >40 \mu m, of dark clumps, of epithelial structures, or of fluorescein leakage, have been retained as indicative of malignancy. Using the presence of two among the five criteria cited above as indicative of malignancy, the authors reported sensitivity and specificity for the diagnosis of malignancy of 97% and 33%, respectively, in a review of 112 pCLE videos from 47 patients [109].

In order to increase specificity for the diagnosis of malignant biliary strictures, an additional series of criteria for inflammatory changes has been proposed in the refined Paris Classification [110]. This latter classification was prospectively validated in a recent multicenter study involving 112 patients with indeterminate biliary strictures [111]; when pCLE findings were added to ERCP assessment, the sensitivity slightly increased from 84% to 89%, while sensitivity for tissue sampling alone was 56% (P<0.01).

**Diagnostic performance of pCLE for the characterization of biliary strictures**

The feasibility of pCLE is high: in two large series that enrolled 222 patients with successful ERCP, pCLE was technically successful in 214 patients (96%) [108, 111]. The diagnostic performance of pCLE for the characterization of indeterminate biliary or biliopancreatic strictures has been reported in three large series (each >50 patients) that evaluated 256 patients [108, 111, 112]. The accuracy for diagnosing malignant stricture was remarkably similar across studies (79%–82%), while sensitivity and specificity were 89%–98% and 67%–77%, respectively. Another study specifically assessed pCLE for the characterization of pancreatic strictures only: pCLE interpretation provided results similar to cytology/histopathology for 15 of 16 patients [113]. With respect to the impact of biliary stenting on diagnostic accuracy, a study reported that diagnostic accuracy was lower (73% vs. 87%) in patients who had biliary stenting or cholangitis prior to pCLE compared with patients with no biliary stenting/cholangitis beforehand [112]. These results need to be confirmed as the difference was not significant (P value 0.42 [two-tailed Fisher exact test]).

The impact of pCLE on management was assessed in one of the abovementioned large studies of biliopancreatic strictures: the endoscopists stated that they would refer the patients to surgery because pCLE confirmed malignancy in 12 of 89 cases (13%) [108]. Another study dedicated to main pancreatic duct strictures reported that pCLE had changed scheduled management, from total pancreatotomy to a Whipple procedure, in four of 18 patients [113]. An additional potential benefit of pCLE that has not been assessed is that it may allow better targeting of biopsy sampling.

**Reproducibility**

Two studies have focused on this topic. In the first study [114], video clips of indeterminate biliary strictures were sent to 6 observers at 5 institutions, 3 of whom had experience with <10 cases. Observers were asked whether each of the five malignancy criteria of the Miami Classification were met or not met, and for their final diagnosis. Interobserver agreement was classified as poor, slight, fair, moderate, substantial, or almost perfect. For all items, agreement was poor to fair, and the final diagnosis had the second worst result (kappa=0.149). Using a similar methodology, the authors then showed that a single teaching session improved interobserver agreement as well as diagnostic accuracy (from 72% to 89%). Again, most observers had little prior experience with the technique [115].

**Complications**

The technique appears relatively safe as no pCLE-related complications have been reported in the three abovementioned large series [108, 111, 112]. With respect to fluorescein, it may rarely cause serious adverse events such as myocardial infarction, anaphylaxis, and seizure. A survey of 16 centers monitoring the short-term safety of fluorescein for CLE procedures (n=2272) found no serious adverse events. All patients experienced yellowish skin discoloration for 1–2h, and mild adverse events occurred in 1.4% of cases (transient hypotension, injection site erythema, diffuse rash) [116].
Conclusion

In summary, pCLE in the biliopancreatic ducts is a promising technique that urgently requires confirmation with regard to rapid learning, diagnostic accuracy, and reproducibility by independent investigators, and also requires cost-benefit analysis.

ESGE technology reviews represent a consensus of best practice based on the available evidence at the time of preparation. They are not rules and should not be construed as establishing a legal standard of care or as encouraging, advocating, requiring, or discouraging any particular treatment.


Institutions
1 Digestive Endoscopy Unit, Catholic University, Rome, Italy
2 Department of Gastroenterology, Hepatopancreatology and Digestive Oncology, Erasme University Hospital, Brussels, Belgium
3 Department of Gastroenterology and Interventional Endoscopy, Klinikum Friedrichshain, Berlin, Germany
4 Department of Internal Medicine, Evangelisches Krankenhaus, Düsseldorf, Germany
5 Department of Gastroenterology, Maggiore Hospital, Crema, Italy
6 Department of Internal Medicine, St. Elisabeth Hospital, Vienna, Austria
7 Endoscopy Unit, Paoli-Calmettes Institute, Marseille, France
8 Department of Gastroenterology, Nuovo Regina Margherita Hospital, Rome, Italy
9 Ceddy Endoscopy Center, Buenos Aires, Argentina

Acknowledgments

The authors thank Paola Cesaro for her help in writing the section on confocal laser endomicroscopy.

References
3 Itoi T, Osanai M, Igarashi Y et al. Diagnostic peroral video cholangioscopy is an accurate diagnostic tool for patients with bile duct lesions. Clin Gastroenterol Hepatol 2010; 8: 934 – 938
4 Ueki T, Mizuno M, Ota S et al. Carbon dioxide insufflation is useful for obtaining clear images of the bile duct during peroral cholangioscopy (with video). Gastrointest Endosc 2010; 71: 1046 – 1051
5 Doi S, Yasuda I, Nakashima M et al. Carbon dioxide insufflation vs. conventional saline irrigation for peroral video cholangioscopy. Endoscopy 2011; 43: 1070 – 1075
17 Sethi A, Chen YK, Austin GL et al. ERCP with cholangiopancreatoscopy may be associated with higher rates of complications than ERCP alone: a single-center experience. Gastrointest Endosc 2011; 73: 251 – 256
21 Chen YK, Pleskov DK. SpyGlass single-operator peroral cholangiopancreatoscopy system for the diagnosis and therapy of bile-duct disorders: a clinical feasibility study (with video). Gastrointest Endosc 2007; 65: 832 – 841
Review


35 Barkay O, Buckst L, Sherman S. Endoscopic transpapillary gallbladder drainage with the SpyGlass cholangiopancreatostomy system. Gastrointest Endosc 2009; 70: 1039 – 1040


47 Pohl J, Ell C. Direct cholangioscopy: new horizons for complex intraductal treatments under direct high-resolution visualization. Gastroenterology 2013; 144: 270 – 271

48 Brauer BC, Fukami N, Chen YK. Direct cholangioscopy with narrowband imaging, chromoendoscopy, and argon plasma coagulation of intraductal papillary mucinous neoplasm of the bile duct (with videos). Gastrointest Endosc 2008; 67: 574 – 576


58 Brauer BC, Chen YK, Ringold DA et al. Peroral pancreatoscopy via the minor papilla for diagnosis and therapy of pancreatic diseases. Gastrointest Endosc 2013; 78: 545 – 549


80 Kim HS, Moon JH, Choi HJ et al. The role of intraductal US in the management of idiopathic recurrent pancreatitis without a definite cause on ERCP. Gastrointest Endosc 2011; 73: 1148 – 1154
88 Donmik D, Wessling J, Conrad B et al. Which imaging modalities should be used for biliary strictures of unknown aetiology? Gut 2007; 56: 1032
91 Jong HoM. The usefulness of IDUS-guided transpapillary bile duct biopsy for the diagnosis of malignant biliary strictures. Endoscopy 2011; 43
97 Inui K, Yoshino J, Okushima K et al. Intraductal EUS. Gastrointest Endosc 2002; 56: 58 – 562
106 Committee AT. Conical laser endomicroscopy. Gastrointest Endosc 2014; 80: 928 – 938